Gary Bhojwani
Analyst · KBW
Thanks, Erik. Long-term care continues to be a significant health care and retirement challenge for middle-income Americans. Regulators and government officials continue to wrestle with an appropriate public solution. In the private sector, options are contracting and forcing those in need to turn to an already strained public system. CNO remains committed to offering long-term care insurance and we will continue to focus on providing affordable high-quality insurance, designed with the needs of our middle-income consumers in mind. Looking at long-term care at CNO moving forward, let me start with our inforce business. The retained business represents a materially reduced risk to the balance sheet. Post-transaction, policies with benefit period of less than one year will represent over 50% of the inforce. Policies with lifetime benefits will fall to under 3%, approximately 5,000 policies down from 11,000 policies. Additionally, long-term care reserves will comprise only 13% of our reserves post transaction, down from 25%. Turning to new business, CNO will focus on products offering shorter benefit periods. It is clear these are the products that resonate most with our customers as the average benefit period across new sales is currently 10 months. Given current customer preference and our desire for products offering shorter benefit periods, we will discontinue sales of long-term care products with benefit periods longer than three years. It is important to note that we expect future sales to contribute to earnings and reserve margins. Additionally, we continue to reinsure 25% of new LTC business, which provides a valuable outside perspective on product design and pricing. Finally, the transition of the administration of this business allows CNO to undertake a more comprehensive review of our middle and back office infrastructure to identify potential ways to increase operating efficiencies and better serve our customers. Moving to Slide 13. I'll close this section of our call by highlighting the key benefits and takeaways for this transformative risk-reduction transaction. This transaction successfully reduces CNO's long-term care exposure by ceding the older and more comprehensive business. The retained business has a much better risk profile, which reduces potential future volatility in earnings and reserves. CNO's differentiated long-term care business enabled us to execute the transaction at reasonable economic terms, while attaining the necessary risk reduction. We were able to transact with a highly rated and well-capitalized counterparty in Wilton Re. The reduction of tail risks significantly enhances the go-forward balance sheet strength of CNO. Derisking marks a step forward in achieving investment-grade ratings by addressing a key rating agency concern. And again, we are pleased to see the positive actions already taken by Moody's and Fitch. Lastly, removing this overhang will allow management to focus its time on accelerating profitable growth and serving the needs of the fast growing and underserved middle-income market. I'd now like to move on to our second quarter earnings results. Beginning with Slide 15, second quarter 2018 was another strong quarter for CNO. We posted solid earnings and capital results and again demonstrated the strength of our franchise. Operating earnings per share were $0.49, up 9%, reflecting benefits from tax reform. Book value per diluted share was $22.62, up 3% sequentially. Five of the seven metrics on the CNO growth scorecard are up this quarter. Although we are pleased with the result, our goal remains to have all seven metrics grow in a consistent and sustainable way. I'll go into more details on the drivers of this quarter strong growth later in the presentation. The expansion of several strategic initiatives from the pilot phase to deployment at scale has yielded encouraging early results. We are confident that we are on the right path to achieve steady and sustained growth across the enterprise. As exciting as these results are, it will take several more quarters of positive results until we will comfortably call it a trend. Our commitment to deploying capital into its highest and best use over time remains unchanged. We returned $77 million in capital to shareholders in the quarter, including $60 million in common stock repurchases. Moving to Slide 16, and our segment production results. Bankers Life total collected premiums were up 2%, primarily driven by a 9% increase in annuity collected premiums. Annuity account values on which spread income is earned increased 5%. This is due to both higher new sales and strong persistency of the inforce. Life and health NAP were down 2% and 5% respectively. The life sales decline was primarily driven by higher declination rates on simplified issue business as a result of the new underwriting requirements implemented late last year. Ultimately, this change should improve our future underwriting margins. Offsetting this decline, fully underwriting -- underwritten universal life sales are up 21% year-to-date. Health sales were partially impacted by higher sales of third-party Medicare Advantage plan, which we do not report as now. Growth in our broker-dealer and registered investment adviser businesses combined with the previously mentioned increase in Medicare Advantage sales drove our fee revenue up 15% over the comparable quarter. Total producing agent count decreased 6% on an average trailing 12-month basis. On a sequential basis, we materially increased the number of first-year producing agents. This is the result of our recent national rollout of recruiting pilots that led to a higher yield of successful new agents and higher first-year agent retention. While it will take time for these improvements to impact the size of the total agent force, we are encouraged by the progress as it validates that our recruiting and retention initiatives are beginning to take hold. We will continue to emphasize agent retention and productivity. Moving to Washington National. Total collected premiums were up 3%. This includes a 3% increase in supplemental health, partially offset by the continued run-off of the closed Medicare Supplement block. Total NAP was up 2% from the year-ago quarter, driven by a 31% increase in worksite life sales. These results stem from continued momentum and initiatives to diversify product offerings and build upon 2017 growth of 15%. Second quarter 2018 PMA worksite sales were up 20% versus the prior year, marking the fifth consecutive quarter of double-digit growth for this channel. The PMA average producing agent count is flat to prior year. New agent recruiting in our individual channel was down slightly. However, it was partially offset by recruiting initiatives in the worksite channel and strong veteran agent retention in both channels. Washington National's growth initiatives continue to advance with positive results. We are seeing early success in our efforts to expand the Washington National geographic footprint with a 14-state expansion program that has generated nearly $2 million of incremental NAP year-to-date. Our pilot to sell short-term care in the PMA individual channel is gaining traction, and we expanded the distribution across additional territories based on its early success. This pilot is particularly encouraging and that it leverages the breadth of the diverse CNO product portfolio and distribution capabilities. For Colonial Penn, total collected premiums were up 2% in the quarter, driven by growth in the block and stable persistency. NAP was up 5% due to higher cost-effective advertising spend and strong sales efficiency. We also continue to see success with our marketing diversification efforts. A 25% increase in web and digital sales this quarter was driven by investments in the platform and in customer experience enhancements. I'll now turn the call over to Erik to discuss our financial results. Erik?